Biomerica provides update on inFoods® IBS expansion
15 avr. 2024 07h47 HE
|
Biomerica, Inc.
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more...
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
28 mars 2024 08h19 HE
|
Biomerica, Inc.
Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) --...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
21 févr. 2024 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
23 janv. 2024 08h19 HE
|
Biomerica, Inc.
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built...
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups
08 nov. 2023 08h19 HE
|
Biomerica, Inc.
Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National...
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
13 oct. 2023 13h10 HE
|
Biomerica, Inc.
Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024
Biomerica Reports First Quarter 2024 Financial Results
13 oct. 2023 06h39 HE
|
Biomerica, Inc.
Biomerica Reports First Quarter 2024 Financial Results. Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024
Biomerica Reports Fiscal 2023 Year End Results
25 août 2023 17h00 HE
|
Biomerica, Inc.
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US ...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 avr. 2023 07h47 HE
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
08 mars 2023 08h19 HE
|
Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...